NZ595037A - Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides - Google Patents

Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides

Info

Publication number
NZ595037A
NZ595037A NZ595037A NZ59503710A NZ595037A NZ 595037 A NZ595037 A NZ 595037A NZ 595037 A NZ595037 A NZ 595037A NZ 59503710 A NZ59503710 A NZ 59503710A NZ 595037 A NZ595037 A NZ 595037A
Authority
NZ
New Zealand
Prior art keywords
cysteamine
inhibition
combination
biofilm
biofilm organisms
Prior art date
Application number
NZ595037A
Other languages
English (en)
Inventor
Neil Deborah O
Derry Mercer
Cedric Charrier
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of NZ595037A publication Critical patent/NZ595037A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ595037A 2009-03-31 2010-03-31 Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides NZ595037A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16539609P 2009-03-31 2009-03-31
GBGB0905451.1A GB0905451D0 (en) 2009-03-31 2009-03-31 Biofilms
PCT/GB2010/000631 WO2010112848A2 (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms

Publications (1)

Publication Number Publication Date
NZ595037A true NZ595037A (en) 2013-07-26

Family

ID=40671951

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595037A NZ595037A (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides

Country Status (21)

Country Link
US (3) US9339525B2 (https=)
EP (1) EP2413949B1 (https=)
JP (1) JP5727994B2 (https=)
KR (1) KR101852784B1 (https=)
CN (2) CN104257645A (https=)
AU (2) AU2010231136B2 (https=)
BR (1) BRPI1012219C1 (https=)
CA (1) CA2755878C (https=)
CY (1) CY1121175T1 (https=)
GB (1) GB0905451D0 (https=)
IL (1) IL215369B2 (https=)
MX (1) MX358018B (https=)
NZ (1) NZ595037A (https=)
PL (1) PL2413949T3 (https=)
RU (1) RU2548786C2 (https=)
SG (2) SG10201400926VA (https=)
SI (1) SI2413949T1 (https=)
TR (1) TR201821161T4 (https=)
UA (1) UA106743C2 (https=)
WO (1) WO2010112848A2 (https=)
ZA (1) ZA201107140B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
TWI403330B (zh) * 2010-03-29 2013-08-01 Rise technology co ltd 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
GB201016733D0 (en) * 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
SG184836A1 (en) 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CN103687610A (zh) 2011-05-12 2014-03-26 史密夫和内修整形外科股份公司 含有蜂蜜曲霉蛋白酶的伤口清创组合物和使用其治疗伤口的方法
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US20140315789A1 (en) * 2011-11-23 2014-10-23 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
ES2991989T3 (es) * 2012-03-23 2024-12-05 Macro Biologics Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos
WO2013170128A1 (en) 2012-05-11 2013-11-14 Smith & Nephew, Inc. Use of seaprose to remove bacterial biofilm
WO2014016979A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物活性調節剤及び微生物の活性を調節する方法
US20160289287A1 (en) * 2013-08-27 2016-10-06 The University Of British Columbia Small cationic anti-biofilm and idr peptides
GB201405891D0 (en) * 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
US11103547B2 (en) 2016-02-04 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
US20210213096A1 (en) * 2016-02-19 2021-07-15 Forschungszentrum Borstel Leibniz-Zentrum Fur Medizin Und Biowssenschaften Means and methods for treating bacterial infections
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
EP3241570A1 (en) * 2016-05-02 2017-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide and hyaluronic acid coatings
EP3454876A4 (en) * 2016-05-12 2019-11-20 The Trustees of The University of Pennsylvania Compositions and methods for inhibiting biofilm deposition and production
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
AU2017304271B2 (en) 2016-07-27 2024-07-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
DK3554491T3 (en) 2016-12-15 2023-05-15 Zambon Spa N-acetylcystein til anvendelse som antibakterielt middel
AU2017381394A1 (en) * 2016-12-22 2019-07-25 The University Of Sydney Biofilm disrupting composition
AU2018205685B2 (en) * 2017-01-05 2023-03-16 Cormedix Inc. Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
EP3573622B1 (en) 2017-01-30 2023-10-18 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
CN108048359B (zh) * 2017-12-27 2020-12-01 广州立白企业集团有限公司 一种牙菌斑生物膜模型的培养方法和优化的生物膜活菌计数法及应用
EP3765057A4 (en) * 2018-03-13 2022-01-05 Peptilogics, Inc. TREATMENT OF IMPLANTS WITH GENERALLY MODIFIED AMPHIPHILIC PEPTIDES
CN108753632A (zh) * 2018-05-25 2018-11-06 安徽中医药大学 一种溶解白念珠菌生物被膜胞外基质的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3866775B1 (en) * 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
CN110402928A (zh) * 2019-08-08 2019-11-05 杭州博菲医疗器械有限公司 一种抑菌功能液及应用该抑菌功能液的导管组件
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
CN111675751B (zh) * 2020-04-08 2022-06-14 天津医科大学口腔医院 一种抗菌肽及其应用
GB202010268D0 (en) * 2020-07-03 2020-08-19 Novabiotics Ltd Nail formulations and treatment regimes
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
AU2042200A (en) * 1998-12-07 2000-06-26 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
PL1778720T3 (pl) * 2004-08-18 2011-03-31 Novabiotics Ltd Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę
WO2007050565A2 (en) 2005-10-25 2007-05-03 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
ZA200805191B (en) * 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
CN101842092A (zh) * 2007-05-25 2010-09-22 奥碧医药(香港)有限公司 用于治疗流感感染的材料和方法
BRPI0907561A2 (pt) * 2008-02-17 2015-08-04 Walcom Animal Science I P 3 Ltd Materiais e métodos para aperfeiçoamento da saúde de camarões
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
US20160106689A1 (en) * 2014-09-22 2016-04-21 Novabiotics Limited Use

Also Published As

Publication number Publication date
IL215369B2 (en) 2023-02-01
MX358018B (es) 2018-08-02
CN102387794A (zh) 2012-03-21
IL215369A (en) 2013-02-03
US20160206575A1 (en) 2016-07-21
MX2011010258A (es) 2011-10-19
KR20120003893A (ko) 2012-01-11
AU2016210742B2 (en) 2017-08-10
WO2010112848A2 (en) 2010-10-07
PL2413949T3 (pl) 2019-04-30
AU2016210742A1 (en) 2016-08-25
JP2012522037A (ja) 2012-09-20
SG10201400926VA (en) 2014-10-30
CA2755878C (en) 2018-04-24
EP2413949B1 (en) 2018-10-10
US9339525B2 (en) 2016-05-17
SI2413949T1 (sl) 2019-02-28
UA106743C2 (uk) 2014-10-10
ZA201107140B (en) 2012-06-27
KR101852784B1 (ko) 2018-04-30
CA2755878A1 (en) 2010-10-07
GB0905451D0 (en) 2009-05-13
US20190175528A1 (en) 2019-06-13
JP5727994B2 (ja) 2015-06-03
TR201821161T4 (tr) 2019-01-21
BRPI1012219C1 (pt) 2021-05-25
SG174278A1 (en) 2011-10-28
CN102387794B (zh) 2015-11-25
EP2413949A2 (en) 2012-02-08
WO2010112848A3 (en) 2011-01-27
AU2010231136A1 (en) 2011-09-29
BRPI1012219B8 (pt) 2020-05-12
CY1121175T1 (el) 2020-05-29
US20120189682A1 (en) 2012-07-26
IL215369B (en) 2022-10-01
RU2548786C2 (ru) 2015-04-20
BRPI1012219A2 (pt) 2016-03-29
AU2010231136B2 (en) 2016-08-04
CN104257645A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
NZ595037A (en) Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides
IL180727A0 (en) Antimicrobial peptides comprising an arginine and/or lysine -containing motif
WO2012002668A3 (en) Novel peptide and use thereof
CA2747703C (en) Compositions and methods for the treatment or the prevention of infections by e. coli
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
NZ597046A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
GB201016733D0 (en) Compounds and their use
WO2008076806A3 (en) Compositions and methods to potentiate colistin activity
UA105018C2 (uk) Акриламідопохідні, застосовні як інгібітори переходу мітохондріальної проникності
NO20081050L (no) Kaspaseinhibitor-prodroger
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
MX2011008043A (es) Derivados de actagardina.
NZ593524A (en) A nonapeptide with anti-tumour activity
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
ITRM20040349A1 (it) Peptidi antibatterici e loro analoghi.
MY159790A (en) Highly bridged peptides from actinomadura namibiensis
MX2009011819A (es) Formulaciones de aminoacido n-halogenado.
WO2014106798A3 (es) Péptidos antimicrobianos, composiciones que los comprende y usos
WO2007125142A8 (es) Péptidos lineales antimicrobianos
UA97633C2 (ru) Циклические антимикробные пептиды
MX2009011817A (es) Formulaciones de aminoacido n-halogenado que contienen acido alifatico.
MD3124C2 (ro) Salicilidentiosemicarbazidaţi de cupru(II) care conţin sulfanilamide
WO2011095768A8 (en) Lantibiotic salts
MX2010014248A (es) Nuevos antibioticos de trinem e inhibidores de beta-lactamasas.
UA96564C2 (en) Peptide

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 MAR 2017 BY RENEWALS TEAM

Effective date: 20140308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2018 BY RENEWALS TEAM

Effective date: 20170325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2019 BY RENEWALS TEAM

Effective date: 20180323

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2020 BY IP CENTRUM LIMITED

Effective date: 20190329

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2021 BY IP CENTRUM LIMITED

Effective date: 20200330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2022 BY IP CENTRUM LIMITED

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2023 BY IP CENTRUM LIMITED

Effective date: 20220308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2024 BY IP CENTRUM LIMITED

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2025 BY IP CENTRUM LIMITED

Effective date: 20240306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAR 2026 BY IP CENTRUM LIMITED

Effective date: 20250327